Symbols / IDXG $1.72 -0.58%
IDXG Chart
About
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier; and RespriDx, a genomic test that enables physicians to differentiate metastatic or recurrent lung cancer. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 47.64M |
| Enterprise Value | 8.45M | Income | 3.63M | Sales | 41.91M |
| Book/sh | -0.07 | Cash/sh | 0.32 | Dividend Yield | — |
| Payout | 0.00% | Employees | 111 | IPO | — |
| P/E | — | Forward P/E | -11.47 | PEG | — |
| P/S | 1.14 | P/B | -25.67 | P/C | — |
| EV/EBITDA | 1.70 | EV/Sales | 0.20 | Quick Ratio | 1.24 |
| Current Ratio | 1.54 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.66 | EPS next Y | -0.15 | EPS Growth | -90.50% |
| Revenue Growth | -28.80% | Earnings | 2022-11-14 16:00 | ROA | 21.90% |
| ROE | — | ROIC | — | Gross Margin | 62.01% |
| Oper. Margin | 13.08% | Profit Margin | 9.06% | Shs Outstand | 27.70M |
| Shs Float | 553.12K | Short Float | 1.18% | Short Ratio | 0.19 |
| Short Interest | — | 52W High | 1.91 | 52W Low | 0.44 |
| Beta | 1.02 | Avg Volume | 9.93K | Volume | 13.00K |
| Target Price | — | Recom | None | Prev Close | $1.73 |
| Price | $1.72 | Change | -0.58% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.70
Latest analyst target
3. DCF / Fair value
$-2.43
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.70
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2021-11-17 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2021-04-09 | main | HC Wainwright & Co. | — → Buy | $9 |
| 2021-01-25 | main | HC Wainwright & Co. | — → Buy | $6 |
| 2020-10-22 | main | HC Wainwright & Co. | — → Buy | $10 |
| 2020-06-26 | main | HC Wainwright & Co. | — → Buy | $11 |
| 2020-04-23 | main | HC Wainwright & Co. | — → Buy | $12 |
| 2020-04-15 | init | Janney Montgomery Scott | — → Buy | — |
| 2020-01-16 | main | Oppenheimer | — → Outperform | $17 |
- Interpace (IDXG) Completes Conversion to Common Stock - GuruFocus ue, 20 Jan 2026 08
- Interpace Diagnostics Guides 2026 Growth After Balance Sheet Cleanup - TipRanks ue, 20 Jan 2026 08
- Interpace Biosciences (IDXG) Stock Price, News & Analysis - MarketBeat Fri, 12 Aug 2016 13
- LabCorp Forms Lab-Alliance With Kentucky-Based Health Firm - Nasdaq Fri, 23 Mar 2018 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 13861386 | 28000000.0 | — | Conversion of Exercise of derivative security at price 2.02 per share. | AMPERSAND 2018, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2026-01-20 00:00:00 | D |
| 1 | 9405941 | 19000001.0 | — | Conversion of Exercise of derivative security at price 2.02 per share. | 1315 CAPITAL II, LP | Beneficial Owner of more than 10% of a Class of Security | — | 2026-01-20 00:00:00 | D |
| 2 | 38475 | nan | — | — | MCCARTHY CHRISTOPHER | Chief Financial Officer | — | 2024-11-29 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -49.00 | 46.83K | -50.87K |
| TaxRateForCalcs | 0.00 | 0.01 | 0.21 | 0.09 |
| NormalizedEBITDA | 8.36M | 4.90M | -1.55M | -769.00K |
| TotalUnusualItems | 0.00 | -7.00K | 223.00K | -559.00K |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -7.00K | 223.00K | -559.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | 6.95M | 2.26M | -5.87M | -7.04M |
| ReconciledDepreciation | 748.00K | 1.60M | 3.50M | 5.37M |
| ReconciledCostOfRevenue | 16.25M | 14.24M | 11.38M | 12.13M |
| EBITDA | 8.36M | 4.89M | -1.33M | -1.33M |
| EBIT | 7.61M | 3.29M | -4.83M | -6.70M |
| NetInterestIncome | -659.00K | -1.01M | -1.01M | -1.04M |
| InterestExpense | 659.00K | 1.01M | 1.01M | 1.04M |
| NormalizedIncome | 6.95M | 2.27M | -6.04M | -6.53M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 6.70M | 1.95M | -21.96M | -14.94M |
| TotalExpenses | 38.82M | 36.07M | 35.68M | 38.88M |
| TotalOperatingIncomeAsReported | 8.11M | 3.96M | -3.62M | -6.34M |
| DilutedAverageShares | 15.73M | 4.36M | 4.24M | 4.13M |
| BasicAverageShares | 4.39M | 4.32M | 4.24M | 4.13M |
| DilutedEPS | 0.40 | 0.18 | -5.18 | -3.61 |
| BasicEPS | 1.42 | 0.19 | -5.18 | -3.61 |
| DilutedNIAvailtoComStockholders | 6.24M | 1.95M | -21.96M | -14.94M |
| NetIncomeCommonStockholders | 6.24M | 1.95M | -21.96M | -14.94M |
| OtherunderPreferredStockDividend | 0.00 | |||
| PreferredStockDividends | 464.00K | |||
| NetIncome | 6.70M | 1.95M | -21.96M | -14.94M |
| NetIncomeIncludingNoncontrollingInterests | 6.70M | 1.95M | -21.96M | -14.94M |
| NetIncomeDiscontinuousOperations | -244.00K | -310.00K | -16.09M | -7.91M |
| NetIncomeContinuousOperations | 6.95M | 2.26M | -5.87M | -7.04M |
| TaxProvision | 4.00K | 17.00K | 29.00K | -705.00K |
| PretaxIncome | 6.95M | 2.28M | -5.84M | -7.74M |
| OtherIncomeExpense | -499.00K | -674.00K | -988.00K | -938.00K |
| OtherNonOperatingIncomeExpenses | -499.00K | -667.00K | -1.21M | -379.00K |
| SpecialIncomeCharges | 0.00 | -7.00K | 223.00K | -559.00K |
| RestructuringAndMergernAcquisition | 0.00 | 7.00K | -223.00K | 559.00K |
| NetNonOperatingInterestIncomeExpense | -659.00K | -1.01M | -1.01M | -1.04M |
| InterestExpenseNonOperating | 659.00K | 1.01M | 1.01M | 1.04M |
| OperatingIncome | 8.11M | 3.96M | -3.84M | -5.76M |
| OperatingExpense | 21.82M | 21.09M | 22.07M | 24.57M |
| DepreciationAmortizationDepletionIncomeStatement | 0.00 | 861.00K | 1.27M | 3.19M |
| DepreciationAndAmortizationInIncomeStatement | 0.00 | 861.00K | 1.27M | 3.19M |
| Amortization | 0.00 | 861.00K | 1.27M | 3.19M |
| AmortizationOfIntangiblesIncomeStatement | 0.00 | 861.00K | 1.27M | 3.19M |
| ResearchAndDevelopment | 676.00K | 636.00K | 703.00K | 1.49M |
| SellingGeneralAndAdministration | 21.14M | 19.60M | 20.10M | 19.88M |
| SellingAndMarketingExpense | 11.65M | 10.23M | 9.12M | 9.18M |
| GeneralAndAdministrativeExpense | 9.49M | 9.36M | 10.97M | 10.71M |
| OtherGandA | 9.49M | 9.36M | 10.97M | 10.71M |
| GrossProfit | 29.93M | 25.06M | 18.23M | 18.80M |
| CostOfRevenue | 17.00M | 14.98M | 13.61M | 14.31M |
| TotalRevenue | 46.93M | 40.04M | 31.84M | 33.12M |
| OperatingRevenue | 46.93M | 40.04M | 31.84M | 33.12M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 130.34K | 96.04K | 71.12K | 32.76K |
| OrdinarySharesNumber | 4.41M | 4.35M | 4.30M | 4.20M |
| ShareIssued | 4.54M | 4.45M | 4.37M | 4.23M |
| NetDebt | 2.83M | 5.84M | 8.84M | 6.77M |
| TotalDebt | 5.86M | 11.19M | 16.09M | 10.72M |
| TangibleBookValue | -2.22M | -55.54M | -63.93M | -44.55M |
| InvestedCapital | 2.07M | -46.20M | -49.41M | -32.98M |
| WorkingCapital | 1.16M | -1.02M | -2.13M | -3.52M |
| NetTangibleAssets | -2.22M | -55.54M | -63.93M | -44.55M |
| CapitalLeaseObligations | 1.57M | 1.85M | 2.43M | 1.28M |
| CommonStockEquity | -2.22M | -55.54M | -63.07M | -42.42M |
| PreferredStockEquity | 46.54M | |||
| TotalCapitalization | -2.22M | -51.30M | -51.91M | -32.98M |
| TotalEquityGrossMinorityInterest | -2.22M | -55.54M | -63.07M | -42.42M |
| StockholdersEquity | -2.22M | -55.54M | -63.07M | -42.42M |
| TreasuryStock | 2.05M | 2.01M | 1.98M | 1.87M |
| RetainedEarnings | -235.38M | -242.08M | -249.02M | -227.06M |
| AdditionalPaidInCapital | 234.81M | 188.15M | 187.52M | 186.11M |
| CapitalStock | 406.00K | 405.00K | 405.00K | 403.00K |
| CommonStock | 406.00K | 405.00K | 405.00K | 403.00K |
| PreferredStock | 0.00 | 0.00 | 46.54M | |
| TotalLiabilitiesNetMinorityInterest | 17.01M | 68.66M | 79.05M | 80.84M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 6.39M | 57.22M | 64.77M | 65.16M |
| OtherNonCurrentLiabilities | 5.21M | 4.97M | 5.22M | 5.96M |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 2.71M | ||
| PreferredSecuritiesOutsideStockEquity | 0.00 | 46.54M | 46.54M | 46.54M |
| NonCurrentDeferredLiabilities | 13.00K | |||
| NonCurrentDeferredRevenue | 13.00K | |||
| LongTermDebtAndCapitalLeaseObligation | 1.18M | 5.71M | 13.01M | 9.96M |
| LongTermCapitalLeaseObligation | 1.18M | 1.47M | 1.85M | 520.00K |
| LongTermDebt | 4.24M | 11.16M | 9.44M | |
| CurrentLiabilities | 10.62M | 11.44M | 14.28M | 15.68M |
| OtherCurrentLiabilities | 660.00K | 660.00K | 858.00K | 3.23M |
| CurrentDeferredLiabilities | 40.00K | |||
| CurrentDeferredRevenue | 40.00K | |||
| CurrentDebtAndCapitalLeaseObligation | 4.67M | 5.48M | 3.08M | 762.00K |
| CurrentCapitalLeaseObligation | 383.00K | 377.00K | 578.00K | 762.00K |
| CurrentDebt | 4.29M | 5.10M | 2.50M | |
| OtherCurrentBorrowings | 4.29M | 5.10M | 2.50M | |
| LineOfCredit | 0.00 | 2.50M | ||
| PayablesAndAccruedExpenses | 5.28M | 5.30M | 10.35M | 11.69M |
| CurrentAccruedExpenses | 3.36M | 3.49M | 9.04M | 10.10M |
| InterestPayable | 0.00 | 120.00K | ||
| Payables | 1.92M | 1.80M | 1.31M | 1.60M |
| TotalTaxPayable | 262.00K | 261.00K | 262.00K | 222.00K |
| AccountsPayable | 1.66M | 1.54M | 1.05M | 1.37M |
| TotalAssets | 14.79M | 13.12M | 15.98M | 38.43M |
| TotalNonCurrentAssets | 3.02M | 2.70M | 3.83M | 26.26M |
| OtherNonCurrentAssets | 45.00K | 45.00K | 45.00K | 22.53M |
| GoodwillAndOtherIntangibleAssets | 0.00 | 861.00K | 2.13M | |
| OtherIntangibleAssets | 861.00K | 2.13M | ||
| Goodwill | 8.43M | |||
| NetPPE | 2.97M | 2.65M | 2.92M | 1.60M |
| AccumulatedDepreciation | -2.85M | -2.54M | -2.38M | -2.22M |
| GrossPPE | 5.82M | 5.20M | 5.30M | 3.82M |
| Leases | 483.00K | 269.00K | 175.00K | 175.00K |
| OtherProperties | 1.61M | 1.86M | 2.44M | 1.28M |
| MachineryFurnitureEquipment | 3.72M | 3.06M | 2.68M | 2.36M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 11.77M | 10.42M | 12.15M | 12.17M |
| OtherCurrentAssets | 22.00K | 24.00K | 180.00K | 70.00K |
| AssetsHeldForSaleCurrent | 0.00 | 3.09M | ||
| RestrictedCash | 0.00 | 500.00K | 250.00K | |
| PrepaidAssets | 535.00K | 590.00K | 390.00K | 584.00K |
| Inventory | 1.21M | 1.23M | 1.22M | 825.00K |
| OtherInventories | 1.22M | 825.00K | ||
| RawMaterials | 1.21M | 1.23M | 1.22M | |
| Receivables | 8.54M | 5.08M | 5.03M | 4.67M |
| AccountsReceivable | 8.54M | 5.08M | 5.03M | 4.67M |
| AllowanceForDoubtfulAccountsReceivable | 0.00 | -72.00K | ||
| GrossAccountsReceivable | 5.03M | 4.74M | ||
| CashCashEquivalentsAndShortTermInvestments | 1.46M | 3.50M | 4.83M | 2.67M |
| CashAndCashEquivalents | 1.46M | 3.50M | 4.83M | 2.67M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 3.77M | 3.32M | -8.01M | -9.07M |
| RepurchaseOfCapitalStock | -32.00K | -108.00K | 0.00 | |
| RepaymentOfDebt | -5.60M | -2.50M | 0.00 | -7.92M |
| IssuanceOfDebt | 0.00 | 3.00M | 17.00M | |
| IssuanceOfCapitalStock | 0.00 | 108.00K | 335.00K | |
| CapitalExpenditure | -876.00K | -470.00K | -322.00K | -354.00K |
| InterestPaidSupplementalData | 625.00K | 1.09M | 971.00K | 369.00K |
| IncomeTaxPaidSupplementalData | 274.00K | 270.00K | 251.00K | 424.00K |
| EndCashPosition | 1.46M | 3.50M | 4.83M | 3.31M |
| BeginningCashPosition | 3.50M | 4.83M | 3.31M | 3.37M |
| ChangesInCash | -2.04M | -1.33M | 1.51M | -58.00K |
| FinancingCashFlow | -5.81M | -5.03M | 3.00M | 8.98M |
| CashFlowFromContinuingFinancingActivities | -5.81M | -5.03M | 3.00M | 8.98M |
| NetOtherFinancingCharges | -161.00K | -2.50M | -435.00K | |
| ProceedsFromStockOptionExercised | -46.00K | -32.00K | -108.00K | 0.00 |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 0.00 | 108.00K | 335.00K | |
| CommonStockPayments | -32.00K | -108.00K | 0.00 | |
| CommonStockIssuance | 0.00 | 108.00K | 335.00K | |
| NetIssuancePaymentsOfDebt | -5.60M | -2.50M | 3.00M | 9.08M |
| NetShortTermDebtIssuance | -5.60M | -2.50M | 1.00M | 1.50M |
| ShortTermDebtPayments | -5.60M | -2.50M | 0.00 | |
| ShortTermDebtIssuance | 0.00 | 1.00M | ||
| NetLongTermDebtIssuance | 0.00 | 2.00M | 9.08M | |
| LongTermDebtPayments | 0.00 | -7.92M | ||
| LongTermDebtIssuance | 0.00 | 2.00M | 17.00M | |
| InvestingCashFlow | -876.00K | -87.00K | 6.21M | -315.00K |
| CashFlowFromContinuingInvestingActivities | -876.00K | -87.00K | 6.21M | -315.00K |
| NetBusinessPurchaseAndSale | 0.00 | 383.00K | 6.53M | 0.00 |
| SaleOfBusiness | 0.00 | 383.00K | 6.53M | 0.00 |
| NetPPEPurchaseAndSale | -876.00K | -470.00K | -322.00K | -315.00K |
| SaleOfPPE | 0.00 | 39.00K | ||
| PurchaseOfPPE | -876.00K | -470.00K | -322.00K | -354.00K |
| OperatingCashFlow | 4.65M | 3.79M | -7.69M | -8.72M |
| CashFlowFromContinuingOperatingActivities | 4.65M | 3.79M | -7.69M | -8.72M |
| ChangeInWorkingCapital | -3.68M | -1.24M | -3.99M | -1.13M |
| ChangeInOtherCurrentLiabilities | -237.00K | -109.00K | -971.00K | -149.00K |
| ChangeInOtherCurrentAssets | 73.00K | -89.00K | -182.00K | -90.00K |
| ChangeInPayablesAndAccruedExpense | -46.00K | -1.26M | -2.71M | -3.04M |
| ChangeInAccruedExpense | -166.00K | -1.75M | -1.97M | -1.22M |
| ChangeInPayable | 120.00K | 489.00K | -735.00K | -1.82M |
| ChangeInAccountPayable | 120.00K | 489.00K | -735.00K | -1.82M |
| ChangeInReceivables | -3.47M | 227.00K | -133.00K | 2.15M |
| ChangesInAccountReceivables | -3.47M | 227.00K | -133.00K | 2.15M |
| OtherNonCashItems | 581.00K | 839.00K | 1.15M | 715.00K |
| StockBasedCompensation | 291.00K | 630.00K | 1.30M | 1.37M |
| ProvisionandWriteOffofAssets | 0.00 | |||
| AssetImpairmentCharge | 0.00 | 12.40M | -140.00K | |
| DeferredTax | 0.00 | -93.00K | 38.00K | |
| DeferredIncomeTax | 0.00 | -93.00K | 38.00K | |
| DepreciationAmortizationDepletion | 748.00K | 1.60M | 3.50M | 5.37M |
| DepreciationAndAmortization | 748.00K | 1.60M | 3.50M | 5.37M |
| Depreciation | 748.00K | 1.60M | 3.50M | |
| OperatingGainsLosses | 63.00K | |||
| GainLossOnInvestmentSecurities | 50.00K | |||
| GainLossOnSaleOfBusiness | 13.00K | |||
| NetIncomeFromContinuingOperations | 6.70M | 1.95M | -21.96M | -14.94M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IDXG
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|